Squarepoint Ops LLC I Mab Transaction History

Squarepoint Ops LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$3.22 - $4.86 $159,538 - $240,793	-49,546 Reduced 74.58%	16,888 $70,000
Q3 2022 Nov 14, 2022	BUY	$4.01 - $12.34 $6,628 - $20,398	1,653 Added 2.55%	66,434 $266,000
Q2 2022 Aug 15, 2022	BUY	$8.27 - $18.43 $535,738 - $1.19 Million	64,781 New	64,781 $732,000
Q1 2022 May 16, 2022	SELL	$12.54 - $46.93 $77,033 - $288,290	-6,143 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$45.28 - $74.5 $715,740 - $1.18 Million	-15,807 Reduced 72.01%	6,143 $291,000
Q3 2021 Nov 15, 2021	BUY	$57.18 - $84.43 $791,943 - $1.17 Million	13,850 Added 170.99%	21,950 $1.59 Million
Q2 2021 Aug 16, 2021	BUY	$47.86 - $83.95 $387,666 - $679,995	8,100 New	8,100 $680,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.9M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.